Successful Treatment of Helicobacter Pylori-Negative Gastric MALT Lymphoma With Rituximab

Chaudhary, Nadeem; Ozer, Howard; Huard, David; Lightfoot, Stan; Mesiya, Sikandar

doi:10.1007/s10620-006-3205-0

Cited by 9 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The toxicity of this treatment was moderate or even mild, but the relapse rate was 36%. An important fact is that patients with translocation t(11;18) are responsive to rituximab treatment [58, 59]. What is more important is that in a study by the International Extranodal Lymphoma Study Group (IELSG), it was confirmed that chlorambucil in combination with rituximab was more effective than chlorambucil alone [60].…”

Section: Treatmentmentioning

confidence: 99%

Helicobacter pyloriInfection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma

Witkowska

Smolewski

2013

Mediators of Inflammation

View full text Add to dashboard Cite

Nowadays, it is believed that the main role in the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma plays Helicobacter pylori infection. This world-wide distributed bacteria is in charge of most cases of not only upper gastrointestinal tract disorders but also some of extragastric problems. Constant stimulation of the immune system causes a B-lymphocytes proliferation, which is considered to be responsible for the neoplastic transformation. On the other hand, there are 10%–20% of patients who do not respond to Helicobacter pylori eradication treatment. This group has often a chromosome translocation, which suggests that there is another unknown, so far, pathogenetic mechanism of MALT lymphoma. Majority of genetic abnormalities are connected with nuclear factor-κB (NF-κB) pathway, which activates the uncontrolled proliferation of neoplastic cells. Translocations already described in studies are t(11;18)(q21;q21), which is the most common, t(14;18)(q32;q21), t(14;18)(q32;q21), and t(3;14)(p14.1;q32). This non-Hodgkin's lymphoma is an indolent type originated outside lymph nodes. In more than 50% of cases, it occurs in the stomach. Occasionally, it can be found in salivary and thyroid gland, lung, breast, bladder, skin, or any other place in the human body. This paper is a review of the current knowledge on etiology, pathogenesis, treatment, and follow-up of gastric MALT lymphoma.

show abstract

Section: Treatmentmentioning

confidence: 99%

Helicobacter pyloriInfection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma

Witkowska

Smolewski

2013

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Analysing a less heterogeneous cohort of patients with early stage disease, i.e. H pylori-negative gastric MZBCL, ORR is increasing over 70% with a complete remission rate of almost 45% [120,121] . Hence, in individual patients, rituximab monotherapy seems to be a good therapeutic option to induce complete lymphoma remission, and the prevalence of the translocation t (11; 18) seems not to have an effect on the lymphoma response to rituximab therapy [120,122] .…”

Section: Monoclonal Antibody (Anti-cd 20) -Rituximabmentioning

confidence: 99%

Therapy of gastric mucosa associated lymphoid tissue lymphoma

Morgner

Schmelz²,

Thiede³

et al. 2007

WJG

View full text Add to dashboard Cite

Gastric mucosa associated lymphoid tissue (MALT) lymphoma has recently been incorporated into the World Health Organization (WHO) lymphoma classification, termed as extranodal marginal zone B-cell lymphoma of MALT-type. In about 90% of cases this lymphoma is associated with H pylori infection which has been clearly shown to play a causative role in lymphomagenesis. Although much knowledge has been gained in defining the clinical features, natural history, pathology, and molecular genetics of the disease in the last decade, the optimal treatment approach for gastric MALT lymphomas, especially locally advanced cases, is still evolving. In this review we focus on data for the therapeutic, stage dependent management of gastric MALT lymphoma. Hence, the role of eradication therapy, surgery, chemotherapy and radiotherapy is critically analyzed. Based on these data, we suggest a therapeutic algorithm that might help to better stratify patients for optimal treatment success.

show abstract

“…According to the authors, the low rate of complete remissions was due to the poor mucosa penetration of the antibodies. The results were slightly better in a less heterogeneous cohort i. e. H. pylori negative gastric MZBCL of MALT-type : the ORR was 70 % with a CR rate of almost 45% [271,272]. The reported efficacy of rituximab therapy was independent of the translocation status t(11;18) [271,273].…”

mentioning

confidence: 93%

S3-Guideline ”Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-Registration-no. 021 / 001

Fischbach

Malfertheiner²,

Hoffmann³

et al. 2009

Z Gastroenterol

View full text Add to dashboard Cite

This guideline updates a prior consensus recommendation of the German Society for Digestive and Metabolic Diseases (DGVS) from 1996. It was developed by an interdisciplinary cooperation with representatives of the German Society for Hygiene and Microbiology, the Society for Pediatric Gastroenterology and Nutrition (GPGE), and the German Society for Rheumatology. The guideline is methodologically based on recommendations of the Association of the Scientific Medical Societies in Germany (AWMF) for providing a systematic evidence-based S 3 level consensus guideline and has also implemented grading criteria according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process. Clinical applicability of study results as well as specifics for Germany in terms of epidemiology, antibiotic resistance status, diagnostics, and therapy were taken into account.

show abstract

Successful Treatment of Helicobacter Pylori-Negative Gastric MALT Lymphoma With Rituximab

Cited by 9 publications

References 14 publications

Helicobacter pyloriInfection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma

Helicobacter pyloriInfection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma

Therapy of gastric mucosa associated lymphoid tissue lymphoma

Contact Info

Product

Resources

About